AMREF

African Medical and Research Foundation

2002

Annual Report & Financial Statements

A glimpse into a healthy tomorrow

AMREF Financial Report 2002

Cover: A glimpse into a healthy tomorrow: A Masaai boy's eye is examined by an AMREF trained community health motivator for trachoma, a disease that is common amongst pastoralists in East Africa. AMREF has trained community health motivators in Entasopia, Kajiado district, Kenya, to help in identifying and managing trachoma among the Masaai pastoralists.

AMREF Headquarters
PO Box 00506-27691
Nairobi
Kenya

Design, layout and production: Rob O'Meara

Printing: Regal Press Kenya Ltd. Nairobi, Kenya

ISBN 9966-874-62-3

Contents

Directors, Officers and Administration

Directors

Mr. Bethuel Kiplagat	(Chairman)
Dr. Michael Smalley	(Director General – Appointed 15 July 2002)
Mr. Bruce Bodner	
Dr. Irwin Friedman	
Mr. Francis Howard	
Dr. Jessica Jitta	
Dr. Adanetch Kidanemariam	
Dr. Eunice Kiereini	
Dr. Adeline Kimambo	
Mr. Iain Knapman	
Dr. Ulrich Laukamm-Josten	
Mr. Hans Tuyt	
Dr. Nizar Verjee	
Dr. Alfonso Villalonga	
Prof. Miriam Were	
Mr. Wilhelm Von Trott	(Appointed 1 March 2002)
Dr. Thomas van der Heijden	(Appointed 4 October 2002)
Mr. Paul Zuckerman	(Appointed 4 October 2002)

Dr. Peter Ngatia acted as Director General from 17 January 2002 until 15 July 2002 when Dr. Michael Smalley was appointed.

Management

Dr. Michael Smalley	Director General
Dr. Peter Ngatia	Director of Programmes
Mr. V. S. Thyagarajan	Director of Finance & Administration
Ms. Lynne Elliot	Director of International Training (up to 2 January 2003)
Ms. Isabel Mbugua	Acting Director of Communication and Fund-raising (up to 25 November, 2002)
Dr. D. Bukenya	Tanzania Country Director
Ms. Mette Kjaer	Kenya Country Director
Ms. Blanche Pitt	South Africa Country Director
Dr. Vincent Oketcho	Uganda Country Director
Dr. Thelma Leifert	Mozambique Country Representative
Dr. John Nduba	Ethiopia Country Representative (with effect from 1 July 2002)

Company Secretary

Mr. V. S. Thyagarajan (Acting)
AMREF
PO Box 27691
00506-Nairobi

Auditors

KPMG Kenya
Certified Public Accountants
16th Floor, Lonrho House
Standard Street
PO Box 40612
00100 Nairobi GPO

Registered Office

Wilson Airport
P O Box 27691
Langata Road
00506-Nairobi

Lawyers

Kaplan & Stratton
7th Floor, Queensway House
PO Box 40111
00100 Nairobi GPO

Bankers

Barclays Bank PLC, London – UK

Citibank N.A., Nairobi – Kenya

Barclays Bank of Kenya Limited, Nairobi – Kenya

National Bank of Kenya Limited, Nairobi – Kenya

National Bank of Commerce (T) Limited, Dar-es-Salaam – Tanzania

Standard Chartered Bank (T) Limited, Dar-es-Salaam – Tanzania

Barclays Bank (U) Ltd, Kampala – Uganda

Uganda Commercial Bank Ltd, Kampala - Uganda

Nedbank, Pretoria - South Africa

Banco Commercial de Mocambique, Maputo – Mozambique

Commercial Bank of Ethiopia, Addis Ababa - Ethiopia

Report of the Directors for the year ended 30 September 2002

The directors have pleasure in submitting their report together with the audited financial statements for the year ended 30 September 2002, which disclose the state of affairs of the company.

1. Objectives of the Foundation

The African Medical and Research Foundation's mission is to improve the health of the disadvantaged in Africa as a means for them to escape poverty and improve the quality of their life.

This mission is to be achieved by developing, testing and promoting the adoption of appropriate models for improving health; contributing to capacity development at all levels and contributing to the development of an enabling environment for health improvement.

AMREF works with communities to implement projects, learns from its activities and uses its knowledge to influence others.

2. Principal activities

The principal activities of the Foundation to achieve the above stated objectives include improving community health, capacity building through training and outreach, and advocating for changes to improve the health and well being of poor people in Africa.

3. Incorporation

The company is incorporated in Kenya as a company limited by guarantee under the Companies Act and is domiciled in Kenya.

4. Results

The results for the year are set out on page 6.

5. Directors

The directors who served since 1 October 2001 are set out on page 1.

6. Auditors

The auditors, KPMG Kenya, were appointed in the year in place of PricewaterhouseCoopers and have indicated their willingness to continue in office in accordance with Section 159(2) of the Companies Act (Cap 486).

7. Approval of financial statements

The financial statements were approved at a meeting of the Directors held on 27 February 2003.

By order of the Board

Michael Smalley

Dr. Michael Smalley
Director
Date: 27 February 2003

Statement of Directors' responsibilities

The Companies Act requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company as at the end of each financial year and of the operating results of the company for that year. It also requires the directors to ensure the company keeps proper accounting records, which disclose with reasonable accuracy the financial position of the company. They are also responsible for safeguarding the assets of the company.

The directors accept responsibility for the financial statements, which have been prepared using appropriate accounting policies supported by reasonable and prudent judgments and estimates, in conformity with International Financial Reporting Standards promulgated by the International Accounting Standards Board and in the manner required by the Companies Act. The directors are of the opinion that the financial statements give a true and fair view of the state of the financial affairs of the company and of its operating results.

The directors further accept responsibility for the maintenance of accounting records which may be relied upon in the preparation of financial statements, as well as adequate systems of internal financial control.

Nothing has come to the attention of the directors to indicate that the company will not remain a going concern for at least the next twelve months from the date of this statement.

Director: Michael Smalley **Dr. Michael Smalley**
Director General

Director: B. A. Kiplagat **Bethuel Kiplagat,**
Chairman Board of Directors

Date : 27 February 2003

Report of the Independent Auditors to the members of African Medical and Research Foundation

(A company Limited by Guarantee)

We have audited the financial statements set out on pages 6 to 17 which have been prepared on the basis of the accounting policies set out in Note 1. We have obtained all the information and explanations that to the best of our knowledge and belief were necessary for the purposes of our audit and to provide a reasonable basis for our opinion. The financial statements are in agreement with the books of account.

Respective responsibilities of directors and independent auditors

As stated on page 4, the directors are responsible for the preparation of financial statements which give a true and fair view of the state of affairs of the company and of its operating results. Our responsibility is to express an independent opinion on the financial statements based on our audit and to report our opinion to you.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing. Those standards require that we plan and perform our audit to obtain reasonable assurance that the financial statements are free from material misstatement. An audit includes an examination, on a test basis, of evidence supporting the amounts and disclosures in the financial statements. It also includes an assessment of the accounting principles used and significant estimates made by the directors, as well as an evaluation of the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Opinion

In our opinion proper books of account have been kept and the financial statements give a true and fair view of the state of the company's financial affairs at 30 September 2002 and of its operating results and cash flows for the year then ended in accordance with International Financial Reporting Standards promulgated by the International Accountings Standards Board and comply with the requirements of the Kenyan Companies Act.

KPMG Kenya

KPMG Kenya
Certified Public Accountants
Nairobi

Date: 27 February 2003

Income and Expenditure Statement for the year ended 30 September 2002

	Note	2002 US$'000	2001 Restated US$'000
Income			
Grants – restricted	2	14,044	12,888
Grants – unrestricted	2	2,607	2,784
Other income	3	2,090	2,220
Net financing income	4	45	99
Total income		**18,786**	**17,991**
Expenditure			
Direct programme activity		14,831	14,276
Programme monitoring and support	5(a)	1,338	1,337
Institutional development	5(b)	858	930
Administration	5(c)	1,721	1,601
Total expenditure		**18,748**	**18,144**
Operating surplus/(deficit) for the year	6	**38**	**(153)**

The notes set out on pages 10 to 17 form an integral part of these financial statements.

Balance Sheet as at 30 September 2002

Assets	Note	2002 US$'000	2001 Restated US$'000
Non-current assets			
Property, plant and equipment	7	4,564	4,624
Current assets			
Inventories	9	436	406
Debtors and prepayments	10	704	838
Grant receivable	11(a)	2,959	2,207
Cash and cash equivalents	12	4,882	4,551
		8,981	8,002
Total Assets		**13,545**	**12,626**
Funds and Liabilities			
Funds (Page 8)			
Capital fund		4,564	4,624
Accumulated surplus		838	529
Aircraft replacement fund		150	-
Aircraft maintenance fund	13	167	129
Health learning materials fund	14	77	77
Total funds		5,796	5,359
Current liabilities			
Creditors and accruals	15	1,912	2,084
Unexpended grants	11(b)	5,837	5,183
		7,749	7,267
Total Funds and Liabilities		**13,545**	**12,626**

The financial statements set out on pages 6 to 17 were approved by the board of directors on 27 February, 2003 and were signed on its behalf by:

Bethuel Kiplagat,
Chairman Board of Directors

Dr. Michael Smalley
(Director General)

The notes set out on pages 10 to 17 form an integral part of these financial statements.

Statement of changes in funds for the year ended 30 September 2002

	Capital Fund	Accumulated surplus	Aircraft replacement fund	Aircraft maintenance fund	Health learning material fund	Total
2001:	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000
At 1 October 2000 as previously stated	4,194	286	-	-	77	4,557
Transfer from current liabilities	-	-	-	282	-	282
Prior year adjustment with respect to leasehold land (Note 8)	(172)	-	-	-	-	(172)
At 1 October 2001 as restated	4,022	286	-	282	77	4,667
Deficit for the year	-	(153)	-	-	-	(153)
Fund transferred on utilisation	-	153	-	(153)	-	-
Depreciation transfer for the year	(293)	293	-	-	-	-
Additions during the year	807	-	-	-	-	807
Disposals	(6)	6	-	-	-	-
Reclassification	94	(56)	-	-	-	38
At 30 September 2001	**4,624**	**529**	**-**	**129**	**77**	**5,359**
2002:						
At 1 October 2001 as previously stated	4,796	529	-	-	77	5,402
Transfer from current liabilities	-	-	-	129	-	129
Prior year adjustment with respect to leasehold land (Note 8)	(172)	-	-	-	-	(172)
At 1 October 2001 as restated	4,624	529	-	129	77	5,359
Surplus for the year	-	38	-	-	-	38
Depreciation transfer	(457)	457	-	-	-	-
Transfer	-	(188)	150	38	-	-
Additions in the year	399	-	-	-	-	399
Disposals	(2)	2	-	-	-	-
At 30 September 2002	**4,564**	**838**	**150**	**167**	**77**	**5,796**

The notes set out on pages 10 to 17 form an integral part of these financial statements.

Cash flow Statement for the year ended 30 September 2002

Cash flows from operating activities

	2002 US$'000	2001 US$'000
Surplus/(deficit) for the year	38	(153)
Adjustments for:		
Capital grant	399	807
Gain on disposal of property, plant and equipment	(8)	(43)
General fund adjustment	-	(56)
Depreciation charge	457	293
Interest income	(45)	(143)
Interest expense	-	44
Operating surplus before working capital changes	**841**	**749**
(Increase)/decrease in inventories	(30)	13
Decrease/(increase) in debtors and prepayments	134	(51)
Net movement in grant receivable/unexpended	(98)	1,082
Decrease in payables	(172)	(32)
	675	1,761
Interest paid	-	(44)
	675	1,717

Cash flow from investing activities

	2002 US$'000	2001 US$'000
Payments to acquire property, plant and equipment	(399)	(807)
Proceeds on disposal of property, plant and equipment	10	49
Interest received	45	143
Net cash used in investing activities	(344)	(615)
Net increase in cash and cash equivalents	331	1,102
Cash and cash equivalents at 1 October 2001 and 2000	4,551	3,449
Cash and cash equivalents at 30 September	**4,882**	**4,551**

The notes set out on pages 10 to 17 form an integral part of these financial statements.

Notes to the Financial Statements for the year ended 30 September 2002

1 Significant accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below:

(a) Basis of preparation

The financial statements are prepared in accordance with and comply with International Financial Reporting Standards promulgated by the International Accounting Standards Board. The financial statements are prepared under the historical cost convention.

(b) Income recognition

i) Grant income is recognised when expenditure is incurred;

ii) Trust fund income is recognised on a receipts basis;

iii) Air Ambulance recoveries are recognised in the year in which the service is provided;

iv) The value of small gifts (e.g. medicines) and some personnel costs from local and overseas donors is not reflected in the financial statements.

(c) Foreign Currency

Transactions in foreign currencies are converted to US dollars using the exchange rate ruling at the date of the transaction. Foreign currency monetary assets and liabilities are translated to US dollars using the exchange rates ruling at the balance sheet date. Resulting exchange gains and losses are recognised in the income and expenditure statement. Non-monetary assets and liabilities denominated in foreign currency are recorded at the exchange ruling at the date of the transaction.

(d) Recognition and measurement of financial instruments

(i) Classification

A financial instrument is a contract that gives rise to both a financial asset of one enterprise and a financial liability of another enterprise.

The financial instruments of the company mainly comprise of:

Originated loans and receivables – These are loans and receivables created by the company for providing money to a debtor. These include debtors, short-term deposits and grants receivable.

Financial liabilities – The company has non-trading financial liabilities, which consist mainly of trade creditors and unexpended grants.

(ii) Recognition

Originated loans and receivables and financial liabilities are recognised on the day they are transferred to the company.

(iii) Measurement

Financial instruments are measured initially at cost, including transaction costs.Subsequent to initial recognition, all non-trading financial liabilities and originated loans and receivables are measured at amortised cost less impairment losses. Amortised cost is calculated using the effective interest rate method. Premiums and discounts, including initial transaction costs, are included in the carrying amount of the related instrument and amortised based on the effective interest rate of the instrument.

(iv) Derecognition

A financial asset is derecognised when the company losses control over the contractual rights that comprise that asset. This occurs when the rights are realised, expire or are surrendered. A financial liability is derecognised when it is extinguished.

(e) Property, plant and equipment

Assets donated to the Foundation are included in the accounts at cost, as estimated by management. Property, plant and equipment purchased for donor-funded health programmes is expensed in the year of purchase. All other property, plant and equipment is initially recorded at cost.

Depreciation is calculated on the straight-line basis to write down the cost of each asset, to its residual value over its estimated useful life as follows:

Buildings	5%
Aircraft	5% - 12.5%
Motor vehicles, medical, surgical and radio equipment	25%
Furniture, fittings and general equipment	12.5%

(f) Inventories

Inventories are valued at the lower of cost and net realisable value. Cost is determined using the weighted average method. Provision is made for obsolete and defective stocks.

(g) Debtors and prepayments

Debtors and prepayments are stated at nominal value less write-down for any amounts expected to be irrecoverable.

(h) Retirement benefit obligations

The company operates a defined contribution retirement benefit scheme for all its local employees. In respect of employees on international contract, the company contributes to individual retirement benefit schemes chosen by the staff concerned.

The company's contributions of 14% of basic pay to the defined contribution scheme and the individual retirement benefit schemes are charged to the Income Statement in the year to which they relate.

(i) Capital fund

The Capital Fund has been created to reflect the amounts donated for and monies spent on property and equipment. The Fund is adjusted through the general fund to reflect movements in property, plant and equipment for acquisition, depreciation and disposals such that the capital fund is equivalent to the net book amount of the property, plant and equipment it represents.

(j) Aircraft replacement fund

The aircraft replacement fund was created during the year with the aim of investing the amount equivalent to the depreciation charged on the caravan aircraft each year to enable the company to replace the aircraft over a period in case grant funds or other funds cannot be raised for the same.

(k) Aircraft Maintenance Fund

Aircraft maintenance fund has been reclassified from current liabilities to funds balances during the year. The aircraft maintenance fund was created to cover for the estimated cost of the next major overhaul of aircraft on the basis of hours flown.

(l) Operating leases

Leases where a significant portion of the risks and rewards of ownership are retained by the lessor, are classified as operating leases. Payments made under operating leases are recognised in the income statement on a straight-line basis over the term of the lease.

(m) Impairment

The carrying value of assets is reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the assets' recoverable amount is estimated and an impairment loss recognised in the income and expenditure account if the carrying amount exceeds its recoverable amount.

(n) Comparative information

Where necessary, comparative information has been adjusted to take into account the effect of adjustments relating to changes in accounting for leasehold land per Note 8, and changes in presentation for the current year.

2 Grant Funds

	2002			2001
	Restricted funds US$'000	**Unrestricted funds US$'000**	**Total funds US$'000**	**Total funds US$'000**
At 1 October:				
Grants receivable	(1,737)	(470)	(2,207)	(2,443)
Unexpended grants	4,103	1,080	5,183	4,337
Net grant funds brought forward	2,366	610	2,976	1,894
Grants received during the year	14,285	2,960	17,245	17,505
Total grants available for operations	16,651	3,570	20,221	19,399
Less: Grant balances at 30 September 2002:				
– Grants receivable (Note 11(a))	2,839	120	2,959	2,207
– Unexpended grants (Note 11(b))	(5,230)	(900)	(6,130)	(5,183)
Transfer to capital fund	(216)	(183)	(399)	(751)
Net grant income	**14,044**	**2,607**	**16,651**	**15,672**

3 Other Income

	2002 US$'000	2001 US$'000
Income from Air Ambulance recoveries	1,181	1,684
Miscellaneous income	909	536
	2,090	**2,220**

4 Net Financing Income

Interest income	45	143
Interest expense	-	(44)
Net financing income	**45**	**99**

5 Expenditure

a) Programme monitoring and support expenditure includes costs relating to the Director of Programmes, Information Technology, Director General and all country level overheads, except finance & administration and communication & fundraising expenses.

b) Institutional development expenditure includes costs relating to the Director General, Director of communication and fundraising, Human Resources and all country level costs relating to communication & fundraising.

c) Administration expenditure includes costs relating to corporate governance, Director General, Director of Finance and Administration, internal audit and all country level costs relating to finance & administration.

6 Operating Surplus/(Deficit)

	2002 US$'000	2001 US$'000
The operating surplus/(deficit) is arrived at after charging/(crediting):		
Depreciation on property, plant and equipment	457	293
Staff costs	7,323	7,229
Auditors' remuneration	17	14
Directors' remuneration:		
– Fees	nil	nil
– Other	50	145
Gain on disposal of property, plant and equipment	(8)	(43)

The following items are included within staff costs:

Termination benefits	186	79
Retirement benefit costs - defined contribution plans	766	776

The number of employees engaged at year-end was 514 (2001-513).

7 Property, Plant and Equipment

	Land & buildings	Aircraft	Motor vehicles	Furniture, fittings & general equipment	Total
	US$'000	US$'000	US$'000	US$'000	US$'000
Cost or valuation					
At 1 October 2001					
as previously stated	3,613	1,516	214	1,364	6,707
Prior year adjustment (Note 8)	(172)	-	-	-	(172)
At 1 October 2001					
as restated	3,441	1,516	214	1,364	6,535
Additions	40	-	110	249	399
Disposal	(15)	-	(27)	(112)	(154)
At 30 September 2002	3,466	1,516	297	1,501	6,780
Depreciation					
At 1 October 2001	385	488	202	836	1,911
Charge for the year	170	151	18	118	457
On disposals	(15)	-	(27)	(110)	(152)
At 30 September 2002	540	639	193	844	2,216
Net book amount					
At 30 September 2002	**2,926**	**877**	**104**	**657**	**4,564**
At 30 September 2001 – Restated	**3,056**	**1,028**	**12**	**528**	**4,624**

In the opinion of the directors, there is no impairment of property, plant and equipment.

Property, plant and equipment which originally cost approximately US$ 715,899 is fully depreciated but still in use. If depreciation had been charged during the year on the cost of these assets the amount of property, plant and equipment and capital funds would have been reduced by US$ 116,152.

8 Repaid operating lease rentals

Leases of land have been classified as operating leases whereas in previous years, such leases were classified as finance leases. This follows clarification received during the year from the International Accounting Standards Board (IASB) and the Institute of Certified Public Accountants of Kenya (ICPAK).

Previously, leasehold land was carried at revalued amounts. Following the reclassification, the net book value of leasehold land has been reclassified from property, plant and equipment to prepaid operating rentals and the revaluation surplus relating to leasehold land has been reversed.

The effect of this change is as detailed below:	2002 US$'000	2001 US$'000
At 1 October 2001 and 2000	-	-
Leasehold land reclassified from property, plant and equipment (Note 7)	172	172
Reversal of revaluation surplus relating to leasehold land	(172)	(172)
At 30 September	**-**	**-**

9 Inventories and work in progress

Aviation spare parts and work in progress	310	269
Printing materials and work in progress	5	21
Printed books and manuals	49	50
Sundry stocks	72	66
	436	**406**

10 Debtors and prepayments

Trade receivables	486	412
National offices	3	39
Programme advances	158	158
Staff debtors	25	36
Others	32	193
	704	**838**

11 Grants Receivable/unexpended

(a) Grants receivable

At 30 September	**2,959**	**2,207**

Grants receivable represent expenditure incurred on projects for which there are commitments from donors for which a donation has not been received by the year-end.

(b) Unexpended grants

At 30 September	6,130	5,183
Less: Unallocated project expenditure	(293)	-
	5,837	**5,183**

Unexpended grants comprise grants and donations received in advance as at the balance sheet date.

	2002 US$'000	2001 US$'000

12 Cash and cash equivalents

Cash at bank and in hand	3,086	3,249
Short term deposits	1,796	1,302
	4,882	**4,551**

The weighted average interest rate on the term deposit was 2.89% (2001 – 4.21%).

13 Aircraft maintenance fund

At 1 October 2001 and 2000	129	282
Additional transfer from accumulated fund during the year	38	-
Utilised during the year	-	(153)
At 30 September	**167**	**129**

14 Health learning materials fund

The Health Learning Materials (HLM) Fund is a deposit of proceeds in Kenya Shillings from the sale of certain printing equipment, the income of which has been set aside for production of health learning materials.

15 Creditors and accruals

Trade creditors	944	1,217
Accruals	968	867
	1,912	**2,084**

16 Bank overdraft

The Foundation has an overdraft facility of KShs 30 million (US$ 400,000). The facility is secured by a floating debenture over the Foundation's fixed and moveable property.

17 Taxation

No tax is provided for in these financial statements, as the Foundation is exempt from income taxation in Kenya in recognition of its charitable status under paragraph 10 of First Schedule of the Income Tax Act (Cap.470).

18 Contingent liabilities

In the ordinary course of business the company has given guarantees amounting to US$ 81,000 (2001: US$ 81,000) to third parties.

19 Capital Commitments

Capital expenditure contracted for at the balance sheet date but not recognised in the financial statements is as follows:

	2002 US$'000	2001 US$'000
Property and equipment	-	35

20 Operating Lease

Operating lease rentals are payable as follows:

Tenancy:	
Less than 1 year	5,397
Between one and five years	55,166
More than five years	-
	60,563

21 Currency

The financial statements are presented in United States of America dollars (US$).

Sources of funding 1997/98-2001/02



	1997/98	1998/99	1999/2000	2000/01	2001/02
Public grants	7.6	8.3	10.1	10.7	11.1
Private donations	5.0	6.1	6.7	5.7	6.0
Other funds	2.1	2.1	2.6	2.6	2.0
Total funds	**14.7**	**16.5**	**19.4**	**19.0**	**19.1**

Expenditure by country 1997/98-2001/02



	1997/98	1998/99	1999/2000	2000/01	2001/02
Kenya	4.9	5.7	7.5	6.9	6.6
Tanzania	2.3	2.3	2.1	2.0	3.3
Uganda	2.4	2.1	3.0	2.6	2.9
Regional	1.9	2.0	2.3	2.9	2.2
Mozambique	0.0	0.2	0.5	0.6	0.6
S. Africa	0.3	0.4	0.3	0.4	0.6
Ethiopia	0.1	0.1	0.2	0.4	0.4
Somalia	0.5	0.5	0.5	0.3	0.1
Rwanda	0.2	0.1	0.1	0.1	0.1
Headquarters	1.7	2.0	1.9	2.0	1.9
Capital	0.4	1.1	1.0	0.8	0.4
Total expenditure	**14.7**	**16.5**	**19.4**	**19.0**	**19.1**

Analysis of expenditure

Priority Intervention Areas	2002 US$000	2001 US$000
Family health	3,773	3,640
HIV/AIDS/TB/STI	3,074	1,744
Training & development of health learning materials	2,998	2,866
Clinical outreach services, emergency response & disaster preparedness	2,688	3,819
Safe water & basic sanitation	1,518	1,399
Malaria	781	808
Direct programme activity expenditure	**14,831**	**14,276**
HQ & Country Offices		
Staff costs	2,611	2,588
Travel & Transport	507	504
Office Costs	504	548
Communications	295	228
Programme monitoring and administration support costs	**3,917**	**3,868**
Total operating expenditure	18,748	18,144
Capital expenditure	399	807
	19,147	**18,951**

Grant funds received by country - 1997/98 - 2001/02

	1997/98 US$ 000	1997/98 Percent %	1998/99 US$ 000	1998/99 Percent %	1999/2000 US$ 000	1999/2000 Percent %	2000/01 US$ 000	2000/01 Percent %	2001/02 US$ 000	2001/02 Percent %
USA	2,805	19.2%	1,751	13.8%	3,569	21.5%	3,039	17.4%	2,891	16.8%
UK	1,996	13.7%	2,411	18.9%	2,789	16.8%	3,211	18.3%	2,537	14.7%
Sweden	2,018	13.8%	1,005	7.9%	1,426	8.6%	555	3.2%	2,134	12.4%
Ireland	830	5.7%	565	4.4%	1,058	6.4%	1,638	9.4%	1,988	11.5%
Italy	408	2.8%	476	3.7%	703	4.2%	971	5.5%	1,541	8.9%
Canada	1,446	9.9%	1,074	8.4%	1,455	8.8%	1,988	11.4%	1,109	6.4%
International organisations	530	3.6%	250	2.0%	555	3.3%	611	3.5%	1,013	5.9%
Tanzania	563	3.9%	469	3.7%	593	3.6%	403	2.3%	884	5.1%
Netherlands	589	4.0%	1,140	9.0%	1,002	6.0%	1,302	7.4%	855	5.0%
Germany	1,361	9.3%	1,480	11.6%	795	4.8%	938	5.4%	737	4.3%
Spain	456	3.1%	563	4.4%	707	4.3%	894	5.1%	651	3.8%
Kenya	609	4.2%	895	7.0%	519	3.1%	486	2.8%	259	1.5%
Austria	20	0.1%	192	1.5%	247	1.5%	366	2.1%	192	1.1%
Denmark	158	1.1%	211	1.7%	338	2.0%	278	1.6%	140	0.8%
Norway	460	3.1%	7	0.1%	278	1.7%	394	2.3%	88	0.5%
France	–	–	–	–	–	–	–	–	29	0.2%
Uganda	–	–	14	0.1%	172	1.0%	140	0.8%	28	0.2%
Switzerland	141	1.0%	200	1.6%	199	1.2%	61	0.3%	3	0.0%
South Africa	129	0.9%	16	0.1%	91	0.5%	50	0.3%	–	–
Other countries	90	0.6%	8	0.1%	128	0.8%	180	1.0%	166	1.0%
Totals	**14,609**	**100.0%**	**12,727**	**100.0%**	**16,624**	**100.0%**	**17,505**	**100.0%**	**17,245**	**100.0%**

The above figures include funds raised and received by AMREF offices in Europe and North America, as listed on Page 24.

Analysis of Grants Received by Country 2001/2002

	Government and official agencies	Foundations, NGOs and general public	Total grant funds received	2001/02 percent	2000/01 percent
	US$ 000	US$ 000	US$ 000		
USA	1,943	948	2,891	16.8%	17.4%
UK	979	1,558	2,537	14.7%	18.3%
Sweden	2,128	6	2,134	12.4%	3.2%
Ireland	1,988	–	1,988	11.5%	9.4%
Italy	–	1,541	1,541	8.9%	5.5%
Canada	1,005	104	1,109	6.4%	11.4%
International Organisations	1,013	–	1,013	5.9%	3.5%
Tanzania	652	232	884	5.1%	2.3%
Netherlands	236	619	855	5.0%	7.4%
Germany	219	518	737	4.3%	5.4%
Spain	651	–	651	3.8%	5.1%
Kenya	38	221	259	1.5%	2.8%
Austria	40	152	192	1.1%	2.1%
Denmark	140	–	140	0.8%	1.6%
Norway	88	–	88	0.5%	2.3%
France	–	29	29	0.2%	–
Uganda	–	28	28	0.2%	0.8%
Switzerland	–	3	3	–	0.3%
South Africa	–	–	–	–	0.3%
Other countries	–	166	166	1.0%	1.0%
Totals	**11,120**	**6,125**	**17,245**	**100.0%**	**100.0%**
2001/02 percentage	**64.5%**	**35.5%**	**100.0%**		
2000/01 percentage	**64.7%**	**35.3%**	**100.0%**		

AMREF International Offices

Founders:
Sir Archibald McIndoe, Dr Thomas D. Rees, Sir Michael Wood

Patrons:
H.E. President Daniel T. arap Moi, CGH, MP; HRH Prince Bernhard of the Netherlands

Headquarters:
African Medical & Research Foundation, PO Box 00506 – 27691 Nairobi, Kenya. Tel. +254 2 605 220. Fax +254 2 609 518. Telex 23254 AMREF. Email: info@amrefhq.org.

Director General:
Dr Michael Smalley.

International Board Chairman:
Amb. Bethuel Kiplagat

WEBSITE: www.amref.org

Africa

Ethiopia
AMREF-Ethiopia, 227B Asmara Road, Worreda 18, Kabele 07, PO Box 20855, Addis Ababa.
Tel. +251 1 630 766. Fax +2511 534 148.
amref@mail.telecom.net.et
Country Representative: Dr John Nduba

Flying Doctors Emergency Services
PO Box , Nairobi, Kenya.
Tel +254 2 501 280. Fax +254 2 336 886.
emergency@flydoc.org
Satellite telephone: 000-873-762-315-580.
Satellite Telefax: 000-873-762-315-581.
Radio frequencies: 9116 LSB And 5796 LSB
Aviation Manager: Capt Jim Heather-Hayes

Kenya
AMREF – Kenya, PO Box 30125, Nairobi.
Tel. +254 2 604 651
Fax +254 2 606 340
info@amrefke.org
Country Director: Ms Mette Kjaer

Mozambique
AMREF _ Mozambique
Av. Marien Ngouabi 112, P.O. Box 433, Maputo - Mozambique
Tel: (+258-1) 414781/3. Fax: (+258-1) 414782.
amrefmoz@amrefmz.org
Country Representative: Ms Thelma Leifert

South Africa
AMREF – South Africa, 329 Pretorious Street
Momentum Centre, West Tower
7th Floor
PRETORIA, 0001.
Tel. +012 320 1332
Fax +012 320 1335
amrefsa@iafrica.com
Country Director: Ms Blanche Pitt

Tanzania
AMREF – Tanzania
Ali Hassan Mwinyi Road, PO Box 2773, Dar es Salaam.
Tel. +255 222 116 610
Fax +255 222 115 823
info@amreftz.org
Country Director: Dr Daraus Bukenya

Uganda
AMREF – Uganda
PO Box 10663, Kampala.
Tel. +256 41 250 319
Fax +256 41 344 565
info@amrefug.org
Country Director: Dr Vincent Oketcho

Europe and North America

Austria

AMREF-Austria, Gesellschaft fuer Medizin und Forschung in Afrika., inc Flying Doctors Service, Waagplatz 3, A5020 Salzburg. Tel: +43 (0)662 840 101. Fax: +43(0)662 847 820. Email: amrefat@salzburg.co.at
Director: Christine Beck-Graninger
Chairman: Dr Walter Schmidjell

Canada

AMREF-Canada, 489 College Street, Suite 407, Toronto, ON. M6G IA5. Tel: +1 (416) 961 6981. Fax: +1 (416) 961 6984. Email: amref.canada@amref.org
Director: John Paterson
Chairman: Alan Torrie

Denmark

Den Afrikanske Laegefond, Gorrisen Federspiel Kierkegaard, 12 H.C. Andersens Boulevard, DK-1553, Copenhagen V. Tel: +45 33 41 41 41. Fax: +45 33 41 41 28. Email: tf@gfklaw.dk
Director: Dr Thomas Federspiel

France

AMREF Médecins Volants, 21 Rue Cassette, 75006 Paris. Tel. +33 06 62 57 94 58. Email: tzarina@club-internet.fr
Director : Zarina de Bagneux
Chairman: François Gautheron

Germany

AMREF Gesellschaft fuer Medizin und Forschung in Afrika e.V., inc Flying Doctors Service, Mauerkircher Str. 155, D-81925, München. Tel: +49 89 98 11 29. Fax: +49 89 98 11 89. Email: info@AMREFgermany.de
Chairman and Director: Leonore Semler

Italy

ROME OFFICE: AMREF-Italia, Fondazione per la Medicina e la Ricerca, Via Luigi Settembrini 30, Roma 00195. Tel: +39 06 320 22 22. Fax: +39 06 320 22 27. Email: info@amref.it.
MILAN OFFICE: Amref Eventi, Via Domenico Cirillo 14, Milano 20154. Tel / Fax: +39 02 345 19 40. Email: milano@amref.it
Director: Thomas Simmons
Chairman: Ilaria Borletti

Monaco

AMREF-Monaco, Galerie Princesse Stephanie 8, Ave des Papalins, 98000 Monaco. Tel: +377 97 77 08 08. Email: amrefmonaco@monaco377.com
Director and Chairman: Anne Wattebled

Netherlands

Stichting AMREF-Nederland, Stevensbloem 269, 2331 JD Leiden. Tel: +31 71 576 9476. Fax: +31 71 576 3777. Email: mail@amref.nl
Director: Constance van Haeften
Chairman: J.J. Tuyt

Spain

Fundación AMREF España, Av. Pío XII, 57. Portal D. Bajo izda. 28016 Madrid
Tel: +34 91 343 02 11
Fax: +34 91 345 04 13
Email: amref@fundacionamref.org
Director: Cristina Vidal
Chairman: Alfonso Villalonga Navarro

Sweden

AMREF-Sweden,
Karlavagen 91, S-115 22 Stockholm, Sweden. Tel: +46 8 662 09 10. Fax: +46 8 667 44 94. Email: amref@telia.com
Director: Lars Engstrom
Chairman: Helena Bonnier

United Kigdom

AMREF-UK, 4 Grosvenor Place, London SW1X 7HJ. Tel: +44 (0)20 7201 6070. Fax: +44 (0)20 7201 6170. Email: amref.uk@amref.org
Director: Alexander Héroys
Chairman: Alistair Boyd CMG

United States of America

AMREF-USA Inc., 19 West 44th St., Room 710, New York, NY 10063. Tel: +1 212 768 2440. Fax: +1 212 768 4230. Email: amrefusa@amrefusa.org
Director: Lisa Meadowcroft
Chairman: Charles H.F. Garner

AMREF's presence in Africa



Key

Main programme countries

Occasional training inputs and consultancies

AMREF

African Medical and Research Foundation

Headquarters:
PO Box 00506 - 27691
Nairobi, Kenya

Telephone: (+254 2) 605220

Main Fax: (+254 2) 609518
Fundraising/Communications Fax: (+254 2) 606345

Telex: 23254 AMREF

Email: info@amrefhq.org

www.amref.org